JPMorgan: China still has catching up to do to become a biotech power
JPMorgan analysts say gaps in fundamental research and geopolitical risks could complicate China's effort to build a world-class biotech ecosystem. Yan Huang, head of China health research at JPMorgan, made the comments in an interview published on Wednesday.

Gaps in fundamental research and growing geopolitical risks could hold back China's efforts to build a world-class biotechnology innovation ecosystem. According to JPMorgan analysts, overseas activity in the sector nonetheless remains strong.
"China still has to catch up in fundamental research, especially in biological and pharmaceutical areas," said Yan Huang, head of China health research at JPMorgan, in an interview published on Wednesday.
The source says the text of the interview is cut off regarding the question of achieving an "ambitious goal" set for the country, so details of that part of the material are not available in the dossier.
Citing the South China Morning Post, JPMorgan's position is based on that publication.
Source: scmp.com





